Patient Empowerment Program: A Rare Disease Podcast

De: n-Lorem Foundation (Dr. Stan Crooke Amy Williford Kim Butler Andrew Serrano Jon Magnuson and Kira Dineen)
  • Resumen

  • Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crroke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Kim Butler, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.
    Copyright 2024 n-Lorem Foundation
    Más Menos
activate_WEBCRO358_DT_T2
Episodios
  • Knowledge is Power: Part 1
    Aug 21 2024

    The knowledge we are gaining at n-Lorem has even more value than benefiting nano-rare patients and their families. These insights will enable scientists to discover new therapeutic targets for both common and rare diseases, fundamentally changing the way we approach health and disease.

    Survey – Patient Empowerment Program PodcastRegister for the 2024 Nano-rare Patient Colloquium

    On This Episode We Discuss:

    • Two most common words in medicine: Health and Disease
    • The Scientific Method
    • The Importance of Single Variables
    • Orthogonal Thinking
    • We Are at a Unique Moment in Medical History
    • Genomics
    • Advances in Omics
    • Biological Networks and AI
    • Facile Collection, Maintenance, Growth and Differentiation in the Lab
    • Antisense Technology
    Más Menos
    35 m
  • Adopting a Rare Son with Paul Compton
    Aug 7 2024

    Paul Compton and his wife Andrea chose to start a family through adoption. Unknown to anyone, one of their adopted boys, Taeson, was the inheritor of DRPLA, a progressive brain disorder caused by a mutation in the ATN1 gene. Determined to find a treatment and advocate for their son and others with the disease, the Comptons established CureDRPLA. In early 2024, Taeson received his initial treatment with an ASO discovered and developed by n-Lorem. Paul discusses his family’s journey and shares his observations of Taeson's progress since beginning treatment.

    In This Episode We Discuss:

    3:05 – Paul's origins in business and finance

    4:32 - Investment banking is different than traditional banking

    7:27 – Opposites attract – Meeting his wife, Andrea, and starting a family through adoption

    10:06 – Paul’s son, Tayson, has a progressive brain disorder known as DRPLA, which is caused by a mutation in the ATN1 gene; Discovering the idea of n-Lorem

    16:03 – Tayson’s journey to a diagnosis

    23:00 – The deterioration of his abilities over the years

    25:00 – The progress Paul has observed in his son since initial treatment

    Links:

    Take our survey and receive an n-Lorem Store coupon code

    Register for the 2024 Nano-rare Patient Colloquium / October 30-31, 2024

    Make Hope Possible with a donation

    Más Menos
    34 m
  • Ion Channel Mutations: The Complexities of Treatment
    Jul 24 2024

    Mutations affecting ion channels are the most common cause of 'applications for treatment' submitted to n-Lorem. These channels regulate the passage of essential electrically charged ions, like sodium, potassium, calcium, and chloride, into cells. Alas, ion channels pose a significant challenge in the ASO discovery process, as there is little room for error due to the need for highly allele-selective ASOs to achieve success. Let’s 'dive into the channel' and explore the complexities of treating patients with ion channel mutations.

    Recently a report on one of our patients with an ion channel mutation was published in Endpoints News highlighting the power of our technology for these disorders. Check it out by clicking the link below.

    Endpoints News (endpts.com) A teenager faced constant seizures. Could a drug developed just for him stop them?

    Podcast Awards - The People's Choice

    Survey – Patient Empowerment Program Podcast

    Register for the 2024 Nano-rare Patient Colloquium

    On This Episode We Discuss:

    • Defining Ion Channels and Ions
    • Health, Homeostasis, and Biological Buffering
    • Multiple forms of the same gene
    • Multiple Isoforms of Gene Product from the same gene
    • Network redundancy
    • Ion Channels are different

    Más Menos
    30 m

Lo que los oyentes dicen sobre Patient Empowerment Program: A Rare Disease Podcast

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.